Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

2.

Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.

Dings RP, Van Laar ES, Webber J, Zhang Y, Griffin RJ, Waters SJ, MacDonald JR, Mayo KH.

Cancer Lett. 2008 Jul 8;265(2):270-80. doi: 10.1016/j.canlet.2008.02.048. Epub 2008 Apr 1.

3.

Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.

Kelner MJ, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P.

Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. doi: 10.1007/s00280-008-0703-0. Epub 2008 Feb 28.

PMID:
18305940
4.

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.

Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, Alberts DS, Weems G, Cullen M, McGuire WP 3rd.

Gynecol Oncol. 2006 Apr;101(1):55-61. Epub 2005 Nov 2.

PMID:
16260029
5.

Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.

Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E.

Cancer Chemother Pharmacol. 2006 Apr;57(4):491-9. Epub 2005 Aug 2.

PMID:
16075278
6.

Cone damage in patients receiving high-dose irofulven treatment.

Lee MS, Gupta N, Penson RT, Loewenstein J, Wepner MS, Seiden MV, Milam AH.

Arch Ophthalmol. 2005 Jan;123(1):29-34.

PMID:
15642808
7.

Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials.

Raymond E, Kahatt C, Rigolet MH, Sutherland W, Lokiec F, Alexandre J, Tombal B, Elman M, Lee MS, MacDonald JR, Cullen M, Misset JL, Cvitkovic E.

Clin Cancer Res. 2004 Nov 15;10(22):7566-74. Erratum in: Clin Cancer Res. 2005 Feb 15;11(4):1684.

8.

Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.

Alexandre J, Raymond E, Kaci MO, Brain EC, Lokiec F, Kahatt C, Faivre S, Yovine A, Goldwasser F, Smith SL, MacDonald JR, Misset JL, Cvitkovic E.

Clin Cancer Res. 2004 May 15;10(10):3377-85.

9.
10.

Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent.

Herzig MC, Trevino AV, Liang H, Salinas R, Waters SJ, MacDonald JR, Woynarowska BA, Woynarowski JM.

Biochem Pharmacol. 2003 Feb 15;65(4):503-13.

PMID:
12566077
11.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG.

J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.

PMID:
10655437
12.

Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF).

Herzig MC, Arnett B, MacDonald JR, Woynarowski JM.

Biochem Pharmacol. 1999 Jul 15;58(2):217-25.

PMID:
10423161
13.

Optimal flexible designs in phase II clinical trials.

Chen TT, Ng TH.

Stat Med. 1998 Oct 30;17(20):2301-12.

PMID:
9819829
14.

Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114).

Woynarowski JM, Napier C, Koester SK, Chen SF, Troyer D, Chapman W, MacDonald JR.

Biochem Pharmacol. 1997 Dec 1;54(11):1181-93.

PMID:
9416969
15.

Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD.

Cancer Res. 1997 Jan 15;57(2):279-83.

16.
17.

Supplemental Content

Support Center